Merck acquires global rights to SciBrunch Therapeutics’ SPR2015, a preclinical oral KRAS G12D inhibitor, in a deal worth up ...
How much of a cancer drug is too much? Patients, researchers challenge FDA-approved dosages Northwestern University economist ...
La société biopharmaceutique Celltrion prévoit de racheter 560 853 actions ordinaires pour un montant maximal de 100 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results